Lead Sponsor

AstraZeneca

Collaborators

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

No

•Diagnosed with type 2 diabetes for at least 6 months
•Have been treated with a stable dose of the following for at least 6 weeks prior to screening: \*immediate or extended release metformin, or \*a sulfonylurea, or \*a fixed-dose sulfonylurea/metformin combination therapy
•Have an HbA1c of 6.6% to 10.0%, inclusive
•Have a Body Mass Index (BMI) of 25 kg/m\^2 to 39.9 kg/m\^2, inclusive

•Are treated with any of the following excluded medications: \*exogenous insulin, thiazolidinedione, or alpha-glucosidase inhibitor for more than 1 week within 6 weeks of screening; \*Symlin injection at any time; \* Byetta injection within 3 months of screening or discontinuation of therapy at any time due to adverse reaction; \*drugs that directly affect gastrointestinal motility; \*use of a weight loss drug (including those available over the counter) within 3 months of screening; \*chronic (lasting longer than 2 weeks) systemic corticosteroids (excluding topical, intranasal, and inhaled preparations) by oral, intravenous, or intramuscular route within 2 months of screening
•Have conditions contraindicating metformin and/or sulfonylurea use
•Have had a change in lipid-lowering agents within 6 weeks of screening
•Have received glucagon-like peptide-1 (GLP-1) analogs, or dipeptidyl peptidase-IV inhibitors (DPP-IV inhibitors) or have previously participated in this study
•Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry